The Gamma-Poisson model, i.e., a Poisson distribution where the parameter lambda is Gamma distributed, has been suggested as a statistical method for determining whether or not micro-organisms are randomly distributed in a food matrix. In this study, we analyse the Gamma-Poisson model to explore some of the properties of the Gamma-Poisson model left unexplored by the previous study. The conclusion of our analysis is that the Gamma-Poisson model distinguishes poorly between variation at the Poisson level and the Gamma level. Estimated parameter values from simulated data-sets showed large variation around the true values, even for moderate sample sizes (n=100). Furthermore, at these sample sizes the likelihood ratio is not a good test statistic for discriminating between the Gamma-Poisson distribution and the Poisson distribution. Hence, to determine if data are randomly distributed, i.e., Poisson distributed, the Gamma-Poisson distribution is not a good choice. However, the ratio between variation at the Poisson level and the Gamma level does provide a measure of the amount of overdispersion.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.fm.2005.01.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system.
Sci Rep
January 2025
Department of Dermatology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Brodalumab, a humanized monoclonal antibody that targets the interleukin-17 receptor A, is primarily used to manage moderate-to-severe plaque psoriasis. Although it has demonstrated favorable efficacy and safety in clinical trials, the strict inclusion and exclusion criteria may not fully reflect its safety profile in real-world settings. As its use becomes more widespread in clinical practice, understanding its safety in real-world applications is crucial.
View Article and Find Full Text PDFAge-stratified analysis of adverse event signals for clarithromycin: a disproportionality analysis using the FDA Adverse Event Reporting System.
Ther Adv Drug Saf
January 2025
College of Pharmacy, Jinan University, Guangzhou, Guangdong 511436, China.
Article Synopsis
- The study examines the adverse events (AEs) linked to clarithromycin, an antibiotic, across different age groups using data from the FDA Adverse Event Reporting System (FAERS).
- Common AEs include vomiting and diarrhea in younger age groups, while older adults experience issues like abnormal taste and drug interactions.
- Eighteen age-specific signals were identified, highlighting the need for tailored monitoring and management of clarithromycin's safety profile in different age demographics.
Adverse events of nusinersen: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database.
Expert Opin Drug Saf
December 2024
Department of Neurology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Chongqing, China.
Article Synopsis
- The study investigates the safety of Nusinersen, an FDA-approved drug for Spinal Muscular Atrophy, using the FAERS database to analyze adverse events.
- It employs various statistical models to identify Nusinersen-related adverse reactions, finding 230 new adverse terms and highlighting potential side effects like cardiac arrest and autism spectrum disorder.
- The findings suggest that younger patients may face risks of upper respiratory infections, while older patients could show symptoms of post-lumbar puncture syndrome, underscoring the need for careful monitoring.
A Bayesian adaptive feasibility design for rare diseases.
Contemp Clin Trials Commun
December 2024
Department of Medicine, Université de Montréal, Québec, Canada.
It is important for researchers to carefully assess the feasibility of a clinical trial prior to the launch of the study. One feasibility aspect that needs to be considered includes whether investigators can expect to successfully achieve the sample size needed for their trial. In this manuscript, we present a Bayesian design in which data collected during a pilot study is used to predict the feasibility of a planned phase III trial.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!